IKBKB and ovarian cancer: To measure how much the anti-tumor responses we achieved with IRF5/IKKβ NP macrophage reprogramming were mediated by host T cells, we next used monoclonal antibodies to deplete CD8+ T cells in mice with established ID8 ovarian cancer (Fig. 5e, f).